logo-loader

Humanigen study of monoclonal antibody in CAR-T therapy presented at Houston conference

Last updated: 09:35 25 Feb 2019 EST, First published: 09:19 25 Feb 2019 EST

A syringe
Findings were presented on behalf of a research team at Mayo Clinic in Rochester, Minnesota

Humanigen Inc (OTCMKTS:HGEN) said Monday that final results of a study on the use of GM-CSF neutralization in CAR-T therapy was presented last week at an annual meeting in Houston.

The Burlingame, California, company said in a statement that Rosalie Sterner presented results of the study on behalf of Dr Saad Kenderian and a research team at Mayo Clinic in  Rochester, Minnesota.

READ: Humanigen study of its monoclonal antibody in CAR-T therapy featured in medical journal

The study was conducted using lenzilumab, the company’s anti-GM-CSF (granulocyte-macrophage colony-stimulating factor) monoclonal antibody, and was recently featured on the cover of the February 14 edition of "blood", the journal of the American Society of Hematology.

The biotech’s lenzilumab monoclonal antibody is designed to reduce the sometimes dangerous side-effects associated with a cancer therapy involving altered T cells. 

Lenzilumab, used in combination with CAR-T therapy, prevents the onset of cytokine release syndrome and significantly reduces neuroinflammation, may prevent impairment of the blood-brain barrier and significantly reduces the neuroinflammation caused by CAR-T, according to Humanigen.

The team found that the therapy enhanced antitumor activity, improved overall survival and improved durability of response with a reduced rate of relapse observed with GM-CSF neutralization.

Shares of Humanigen were down $0.12 to $1.24 in Friday’s OTC Markets trading.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com
 

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 25 minutes ago